---
figid: PMC10520974__fimmu-14-1268745-g004
figtitle: Regulatory mechanisms of lncRNAs in cancer cell antigen presentation
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10520974
filename: fimmu-14-1268745-g004.jpg
figlink: /pmc/articles/PMC10520974/figure/F4
number: F4
caption: Regulatory mechanisms of lncRNAs in cancer cell antigen presentation. The
  lncRNA LINK-A supports the interaction between inhibitory GPCR and PIP3 pathways,
  leading to downregulation of cAMP and consequent inhibition of PKA-mediated TRIM71
  phosphorylation. As a result, LINK-A promotes K48-polyubiquitination-mediated degradation
  of the PLC components including tapasin, TAP1, TAP2, and CALR, constituting a resistance
  strategy for immunological cancer escape. The linRNA EPIC1 causes the epigenetic
  silencing of antigen presentation genes (e.g., HLA-A, HLA-B, HLA-C) and antigen
  processing genes (e.g., ERAP1/2, TAP1/2 and tapasin) through interaction with EZH2.
  These lncRNAs promotes cancer resistance to immunotherapy. TCR, T cell receptor;
  MHC-I, major histocompatibility complex class I; GPCR, G-protein-coupled receptor;
  PIP3, phosphatidylinositol- (3,4,5)-triphosphate; cAMP, cyclic adenosine monophosphate;
  PKA, protein kinase A; TRIM71, tripartite motif-containing 71; TAP1, transporter
  associated with antigen processing 1; TAP2, transporter associated with antigen
  processing 2; CALR, calreticulin; PLC, peptide-loading complex; HLA-A, human leukocyte
  antigen A; HLA-B, human leukocyte antigen B; HLA-C, human leukocyte antigen C; ERAP1/2,
  endoplasmic reticulum aminopeptidase 1/2; EZH2, zeste homolog 2.
papertitle: 'Noncoding RNAs as an emerging resistance mechanism to immunotherapies
  in cancer: basic evidence and therapeutic implications'
reftext: Man Wang, et al. Front Immunol. 2023;14(8):1268745.
year: '2023'
doi: 10.3389/fimmu.2023.1268745
journal_title: Frontiers in Immunology
journal_nlm_ta: Front Immunol
publisher_name: Frontiers Media S.A.
keywords: cancer | tumor microenvironment | immunotherapy resistance | ncRNAs | tumor
  immunity | ncRNA-based therapies
automl_pathway: 0.9548374
figid_alias: PMC10520974__F4
figtype: Figure
redirect_from: /figures/PMC10520974__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10520974__fimmu-14-1268745-g004.html
  '@type': Dataset
  description: Regulatory mechanisms of lncRNAs in cancer cell antigen presentation.
    The lncRNA LINK-A supports the interaction between inhibitory GPCR and PIP3 pathways,
    leading to downregulation of cAMP and consequent inhibition of PKA-mediated TRIM71
    phosphorylation. As a result, LINK-A promotes K48-polyubiquitination-mediated
    degradation of the PLC components including tapasin, TAP1, TAP2, and CALR, constituting
    a resistance strategy for immunological cancer escape. The linRNA EPIC1 causes
    the epigenetic silencing of antigen presentation genes (e.g., HLA-A, HLA-B, HLA-C)
    and antigen processing genes (e.g., ERAP1/2, TAP1/2 and tapasin) through interaction
    with EZH2. These lncRNAs promotes cancer resistance to immunotherapy. TCR, T cell
    receptor; MHC-I, major histocompatibility complex class I; GPCR, G-protein-coupled
    receptor; PIP3, phosphatidylinositol- (3,4,5)-triphosphate; cAMP, cyclic adenosine
    monophosphate; PKA, protein kinase A; TRIM71, tripartite motif-containing 71;
    TAP1, transporter associated with antigen processing 1; TAP2, transporter associated
    with antigen processing 2; CALR, calreticulin; PLC, peptide-loading complex; HLA-A,
    human leukocyte antigen A; HLA-B, human leukocyte antigen B; HLA-C, human leukocyte
    antigen C; ERAP1/2, endoplasmic reticulum aminopeptidase 1/2; EZH2, zeste homolog
    2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - LINC01139
  - CD8A
  - CD8B
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - TAP1
  - SEC14L2
  - TAP2
  - SEC14L3
  - HLA-A
  - CALR
  - HLA-B
  - EPIC1
  - HLA-C
  - TRIM71
  - EZH2
  - ERAP2
  - ERAP1
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - CAMP
  - Nucleus
  - Cancer
---
